ARTICLE | Clinical News
Cellular BioMedicine to test stem cell therapy in Chinese Phase II for knee osteoarthritis
February 15, 2019 6:54 PM UTC
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) said China's National Medical Products Administration (NMPA) approved an IND for a Phase II trial of AlloJoin to treat knee osteoarthritis.
The product is an allogeneic adipose-derived mesenchymal progenitor cell therapy...
BCIQ Company Profiles